IGM Biosciences, Inc. (IGMS) came out with quarterly earnings of $1.58 per share, beating the Zacks

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t

MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a bio

IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $0.86 per share versus the Zacks Cons

IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earni

IGM Biosciences (IGMS) has become technically an oversold stock now, which implies exhaustion of the

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf

NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on be

NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on be

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf

NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf

NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has

NEW YORK CITY, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on be

Stifel downgraded IGM Biosciences to Hold from Buy with a price target of $2.50, down from $27. Th f

Morgan Stanley analyst Michael Ulz downgraded IGM Biosciences to Underweight from Equal Weight with

BMO Capital downgraded IGM Biosciences to Market Perform from Outperform with a price target of $2,

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achiev

– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Compan

IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.01 per share versus the Zacks Cons

Small-cap stocks are surging ahead of the expected interest rate cut by the Federal Reserve, outperf

Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reporte

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 30 points on Monday.

  Tuesday saw 132 companies set new 52-week lows.

  On Wednesday, 311 stocks hit new 52-week lows.

  On Thursday, 283 companies set new 52-week lows.

  On Wednesday, 179 companies reached new 52-week lows.

  On Tuesday, 164 companies achieved new lows for the year.

  During Monday's session, 201 stocks hit new 52-week lows.

  During Tuesday's trading, 188 companies set new 52-week lows.

U.S. stocks traded mixed, with the Dow Jones dropping around 50 points on Thursday. Here are some bi

  On Tuesday, 65 companies set new 52-week lows.

  Monday's session saw 114 companies set new 52-week lows.

  On Wednesday, 220 stocks hit new 52-week lows.

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quart

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.

  During Tuesday's session, 454 stocks hit new 52-week lows.

    On Wednesday, 348 companies hit new 52-week lows.

  On Tuesday, 88 companies set new 52-week lows.

    On Thursday, 615 stocks hit new 52-week lows.

Gainers

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its

Gainers

Gainers Greenwich Lifesciences Inc (NASDAQ: GLSI) shares jumped 998.1% to close at $57.10 on Wedn

  Before 10 a.m. ET on Wednesday, 322 companies hit new 52-week highs.

Gainers Curis, Inc. (NASDAQ: CRIS) stock climbed 354.9% to close at $6.55 on Tuesday after the co